Bridging regenerative medicine based therapies into the 21st Century: solo or symphony?
Keywords:basic research, cardiovascular disease, outcome research, translational research
Clinical translation in the field of regenerative medicine means manufacturing a safe, reproducible and effective clinical product for the benefit of patients. This represents the ultimate goal of applied research, but beyond researchers and clinicians, multiple intermediate players are involved, including other researchers, reviewers, funding agencies, scientific societies, guideline authors, and policy regulators. Consequently, bridging translational research and regenerative medicine therapies into the 21st Century requires a resolute effort. We envisage that strategic and synergistic efforts in seven key areas will facilitate the mainstream adoption and implementation of regenerative medicine based therapies.
Nowbar AN, Mielewczik M, Karavassilis M, Dehbi HM, Shun-Shin MJ, Jones S, Howard JP, Cole GD, Francis DP; DAMASCENE writing group. Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. BMJ. 2014 Apr 28;348:g2688. doi: 10.1136/bmj.g2688. Review
Gaspar R, Aksu B, Cuine A, Danhof M, Takac MJ, Linden HH, Link A, Muchitsch EM, Wilson CG, Ohrngren P, Dencker L. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020. Eur J Pharm Sci. 2012 Dec 18;47(5):979-87. doi: 10.1016/j.ejps.2012.09.020.
Fabrizi C, Angelini F, Chimenti I, Pompili E, Somma F, Gaetani R, Messina E, Fumagalli L, Giacomello A, Frati G. Thrombin and thrombin-derived peptides promote proliferation of cardiac progenitor cells in the form of cardiospheres without affecting their differentiation potential. J Biol Regul Homeost Agents. 2011 Apr-Jun;25(2 Suppl):S43-51
Siciliano C, Ibrahim M, Scafetta G, Napoletano C, Mangino G, Pierelli L, Frati G, De Falco E. Optimization of the isolation and expansion method of human mediastinal-adipose tissue derived mesenchymal stem cells with virally inactivated GMP-grade platelet lysate. Cytotechnology. 2013 Dec 4
Chimenti I, Gaetani R, Forte E, Angelini F, De Falco E, Zoccai GB, Messina E, Frati G, Giacomello A. Serum and supplement optimization for EU GMP-compliance in cardiospheres cell culture. J Cell Mol Med. 2014 Apr;18(4):624-34. doi: 10.1111/jcmm.12210
Frati P, Frati G, Gulino M, Montanari Vergallo G, Di Luca A, Fineschi V. Stem cell therapy: from evidence-based medicine to emotion-based medicine? The long Italian way for a scientific regulation. Stem Cell Res Ther. 2013 Oct 11;4(5):122. doi: 10.1186/scrt333.
Rham C, Villard J. Potential and limitation of HLA-based banking of human pluripotent stem cells for cell therapy. J Immunol Res. 2014;2014:518135. doi: 10.1155/2014/518135.
Webb S. Banking on cord blood stem cells. Nat Biotechnol. 2013 Jul;31(7):585-8.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under aÂ Creative Commons Attribution LicenseÂ that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open AccessÂ and Benefits of Publishing Open Access).